Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "S-1"

774 News Found

European Commission approves Pfizer’s Velsipity for patients with moderately to severely active ulcerative colitis
Drug Approval | February 20, 2024

European Commission approves Pfizer’s Velsipity for patients with moderately to severely active ulcerative colitis

VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU


Scandron receives India's first logistics drone type-certification from DGCA
Supply Chain | February 20, 2024

Scandron receives India's first logistics drone type-certification from DGCA

The launch of a DGCA Type Approved Logistics Drone facilitates critical medical deliveries to remote regions


Lupin receives approval from USFDA for Minzoya
Drug Approval | February 17, 2024

Lupin receives approval from USFDA for Minzoya

Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy


Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
News | February 16, 2024

Marksans Q3 FY24 revenue up 22% at Rs 586 Cr

Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%


Zydus Lifesciences Q3 FY24 PAT up 26.8%
News | February 10, 2024

Zydus Lifesciences Q3 FY24 PAT up 26.8%

Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.


AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
Diagnostic Center | January 31, 2024

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation


Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab
News | January 29, 2024

Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America


Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
News | January 10, 2024

Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb


Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore
News | January 08, 2024

Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore

Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh


Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets
Drug Approval | January 04, 2024

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US